Full results from two Lilly trials of the novel triple hormone receptor agonist show reductions in A1c, osteoarthritis knee pain, and obstructive sleep apnea.
Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results